Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use

Neurology

Volumn 72, Issue 10, 2009, Pages 911-914

  Herzog, A G ^a   Blum, A S ^b   Farina, E L ^a   Maestri, X E ^b   Newman, J ^b   Garcia, E ^c   Krishnamurthy, K B ^a   Hoch, D B ^d   Replansky, S ^d   Fowler, K M ^e   Smithson, S D ^a   Dworetzky, B A ^d   Bromfield, E B ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c NEWTON WELLESLEY HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Brigham and Women's Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

DEPAKOTE ER; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; LAMOTRIGINE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ANTICONVULSIVE AGENT; ORAL CONTRACEPTIVE AGENT; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPILEPSY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; PRIORITY JOURNAL; BODY MASS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; BODY MASS INDEX; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; EPILEPSY; FEMALE; FOLLICULAR PHASE; HUMANS; LUTEAL PHASE; MENSTRUAL CYCLE; MIDDLE AGED; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 64049097153     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000344167.78102.f0     Document Type: Article

References (20)

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; 350:1-36.
2. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-272.
3. Shavit G, Lerman P, Korczyn AD, Kivity S, Bechar M, Gitter S. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984;34:959-961.
4. Rosciszewska D, Buntner B, Guz I, Zawisza L. Ovarian hormones, anticonvulsant drugs and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986;49:47-51.
5. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-323.
6. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:523-531.
7. Sabers A, Buchholt JM, Udall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Research 2001;47:151-154.
8. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurol 2003; 61:570-571.
9. Sidhu J, Bulsara S, Job S, et al. A bi-directional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive pill in healthy subjects. Epilepsia 2004; 45(suppl 7):330.
10. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48: 484-489.
11. Herzog AG, Farina EL, Blum AS. Fluctuation in serum valproate levels with oral contraceptive use. Epilepsia 2005;46:970-971.
12. Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:23-29.
13. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144: 511-518.
14. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
15. Dickins M, Chen C. Lamotrigine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs (5th ed.). Philadelphia: Lippincott Williams & Wilkins; 2002:370-379.
16. Levy RH, Shen DD, Abbott FS, Riggs KW, Hachad H. Valproic acid: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs (5th ed.). Philadelphia: Lippincott Williams & Wilkins; 2002:780-800.
17. Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67:1297-1299.
18. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088.
19. Quigg M, Fowler KM, Herzog AG, and the Progesterone Trial Study Group. Circalunar and ultralunar periodicities in women with partial seizures. Epilepsia 2008;49:1081-1085.
20. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:431-434.